Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
CUMBERLAND PHARMACEUTICALS INC (CPIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "Cumberland Pharmaceuticals Reports First Quarter 2023"
11/09/2021 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE"
05/11/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, Tennessee - Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million. The company also recorded an additional $750,000 in revenue during the third quarter associated with divested product rights for two brands it is no longer distributing. The Company's financial position included $96 million in total assets - with $27 million in cash, $48 million of total liabilities, and $48 million of shareholders’ equity at the end of the quarter. "As we move to the close of 2020, we recognize that it has been a particularly difficult year ..."
08/11/2020 8-K Quarterly results
05/20/2020 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, TN - Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results. Net revenues from continuing operations during the quarter were $8.3 million. Total revenues were $9.1 million, as the company recorded an additional $750,000 in revenue in the first quarter associated with divested product rights. The Company's financial position included over $97 million in total assets, $48 million of total liabilities, and nearly $50 million of shareholders’ equity at the end of the quarter. "Our thoughts go out to those currently suffering from the novel coronavir..."
08/05/2016 8-K Form 8-K - Current report
05/13/2016 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS"
05/08/2015 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
11/07/2014 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS"
08/08/2014 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
05/16/2014 8-K Quarterly results
Docs: "CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"
11/06/2013 8-K Form 8-K - Current report
08/09/2013 8-K Quarterly results
05/03/2013 8-K Form 8-K - Current report
11/01/2012 8-K Form 8-K - Current report
08/02/2012 8-K Form 8-K - Current report
05/03/2012 8-K Form 8-K - Current report
11/03/2011 8-K Form 8-K - Current report
08/05/2011 8-K Form 8-K - Current report
05/05/2011 8-K Form 8-K - Current report
11/12/2010 8-K Form 8-K - Current report
08/16/2010 8-K Form 8-K - Current report
08/28/2009 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy